News on noninvasive prenatal testing, carrier screening, and preimplantation genetic screening.
The company launched in November a survey-based test for screening patients for preterm birth risk that it plans to pair with a mass spectrometry-based assay.
The company said it expects core molecular testing revenue between $115 million and $125 million and SARS-CoV-2 revenue between $15 million and $20 million.
Last year, the company processed more than 1 million tests, most of them for its reproductive health business, but interest in Prospera and Signatera is growing.
The study aims to evaluate how pairing Sera's PreTRM test with clinical interventions may mitigate preterm birth risk, improve neonatal outcomes, and reduce healthcare costs.
Ravgen has alleged that several leading NGS-based non-invasive prenatal testing and oncology assays infringe two patents held by the firm.
